Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.

@article{Lee2010IronCT,
  title={Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.},
  author={Jong Wook Lee and Sung Soo Yoon and Zhi Xiang Shen and Arnold Ganser and Hui-chi Hsu and Dany Habr and Gabor Domokos and Bernard Roubert and John B. Porter},
  journal={Blood},
  year={2010},
  volume={116 14},
  pages={
          2448-54
        }
}
The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population. After 1 year, median serum ferritin decreased significantly from 3254 ng/mL at baseline to 1854 ng/mL (P < .001). Decreases occurred in chelation-naive (3229-1520 ng/mL; P < .001, last-observation-carried-forward analysis), and previously chelated… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS, ESTIMATED 48% COVERAGE

70 Citations

051015'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 70 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Epidemiology EFFICACY AND SAFETY OF DEFERASIROX IN AA 2453 BLOOD

  • E Montane, L Ibanez, X Vidal
  • For personal use only. on April
  • 2010

Similar Papers

Loading similar papers…